タイトル | Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. |
---|
ジャーナル・号・ページ | J. Med. Chem., Vol. 65, Page 7818-7832, Year 2022 |
---|
掲載日 | 2021年12月9日 (構造データの登録日) |
---|
著者 | Dampalla, C.S. / Rathnayake, A.D. / Galasiti Kankanamalage, A.C. / Kim, Y. / Perera, K.D. / Nguyen, H.N. / Miller, M.J. / Madden, T.K. / Picard, H.R. / Thurman, H.A. ...Dampalla, C.S. / Rathnayake, A.D. / Galasiti Kankanamalage, A.C. / Kim, Y. / Perera, K.D. / Nguyen, H.N. / Miller, M.J. / Madden, T.K. / Picard, H.R. / Thurman, H.A. / Kashipathy, M.M. / Liu, L. / Battaile, K.P. / Lovell, S. / Chang, K.O. / Groutas, W.C. |
---|
リンク | J. Med. Chem. / PubMed:35638577 |
---|
手法 | X線回折 |
---|
解像度 | 1.45 - 2.1 Å |
---|
構造データ | PDB-7t3y: Structure of MERS 3CL protease in complex with inhibitor 8c 手法: X-RAY DIFFRACTION / 解像度: 1.9 Å PDB-7t3z: Structure of MERS 3CL protease in complex with inhibitor 9c 手法: X-RAY DIFFRACTION / 解像度: 1.95 Å PDB-7t40: Structure of MERS 3CL protease in complex with inhibitor 10c 手法: X-RAY DIFFRACTION / 解像度: 1.7 Å PDB-7t41: Structure of MERS 3CL protease in complex with inhibitor 14c 手法: X-RAY DIFFRACTION / 解像度: 2.1 Å PDB-7t42: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 2c 手法: X-RAY DIFFRACTION / 解像度: 1.6 Å PDB-7t43: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 3c 手法: X-RAY DIFFRACTION / 解像度: 1.7 Å PDB-7t44: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 4c 手法: X-RAY DIFFRACTION / 解像度: 1.45 Å PDB-7t45: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 7c 手法: X-RAY DIFFRACTION / 解像度: 1.65 Å PDB-7t46: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 8c 手法: X-RAY DIFFRACTION / 解像度: 1.45 Å PDB-7t48: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 9c 手法: X-RAY DIFFRACTION / 解像度: 1.9 Å PDB-7t49: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 10c 手法: X-RAY DIFFRACTION / 解像度: 1.75 Å PDB-7t4a: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 11c 手法: X-RAY DIFFRACTION / 解像度: 1.8 Å PDB-7t4b: Structure of SARS-CoV-2 3CL protease in complex with inhibitor 14c 手法: X-RAY DIFFRACTION / 解像度: 1.6 Å |
---|
化合物 | ChemComp-F5L: (1R,2S)-1-hydroxy-2-{[N-({[7-(2-methylpropanoyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-F8C: (1S,2S)-1-hydroxy-2-{[N-({[7-(2-methylpropanoyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FHS: (1S,2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]-2-{[N-({[7-(phenylacetyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}propane-1-sulfonic acid
ChemComp-FEY: (1R,2S)-2-{[N-({[(2r,4R)-7-acetyl-7-azaspiro[3.5]non-5-en-2-yl]oxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FV5: (1R,2S)-1-hydroxy-2-{[N-({[7-(methanesulfonyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FVE: (1S,2S)-1-hydroxy-2-{[N-({[7-(methanesulfonyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FWI: (1R,2S)-2-{[N-({[1-(tert-butoxycarbonyl)azetidin-3-yl]methoxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3R)-2-oxo-2,3-dihydro-1H-pyrrol-3-yl]propane-1-sulfonic acid
ChemComp-FZI: (1S,2S)-2-{[N-({[1-(tert-butoxycarbonyl)azetidin-3-yl]methoxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3R)-2-oxo-2,3-dihydro-1H-pyrrol-3-yl]propane-1-sulfonic acid
ChemComp-FIK: (1S,2S)-2-[(N-{[(2-acetyl-2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FIW: (1R,2S)-1-hydroxy-2-{[N-({[2-(2-methylpropanoyl)-2-azaspiro[3.3]heptan-6-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FN2: (1S,2S)-1-hydroxy-2-[(N-{[(2-methyl-2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-FP8: (1R,2S)-1-hydroxy-2-[(N-{[(2-methyl-2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-ESS: (1R,2S)-2-[(N-{[(2-azaspiro[3.3]heptan-6-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-ET6: (1S,2S)-1-hydroxy-2-{[N-({[2-(methanesulfonyl)-2-azaspiro[3.3]heptan-6-yl]oxy}carbonyl)-L-leucyl]amino}-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-EW9: (1S,2S)-2-{[N-({[7-(tert-butoxycarbonyl)-7-azaspiro[3.5]nonan-2-yl]oxy}carbonyl)-L-leucyl]amino}-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-EQS: (1S,2S)-2-[(N-{[(7-cyano-7-azaspiro[3.5]nonan-2-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
ChemComp-EO6: (1R,2S)-2-[(N-{[(7-cyano-7-azaspiro[3.5]nonan-2-yl)oxy]carbonyl}-L-leucyl)amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid
|
---|
由来 | - middle east respiratory syndrome-related coronavirus (isolate united kingdom/h123990006/2012) (ウイルス)
- severe acute respiratory syndrome coronavirus 2 (ウイルス)
|
---|
キーワード | HYDROLASE/HYDROLASE INHIBITOR / PROTEASE / MERS 3CL protease Inhhibitors / hydrolase / HYDROLASE-HYDROLASE INHIBITOR complex / COVID-19 / severe acute respiratory syndrome coronavirus 2 / SARS-CoV-2 3CL protease Inhhibitors |
---|